Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?

摘要: Non-Hodgkin lymphoma is a diverse group of lymphocyte-derived neoplasms. Although heterogeneous malignancies, it has become apparent that epigenetic alterations, such as disturbances DNA methylation and histone modification, are common occurrence in both B cell T lymphomas, contributing to lymphomagenesis. As result, the use targeted therapy been incorporated into various pre-clinical clinical studies, demonstrating significant efficacy lymphoma, with vorinostat becoming first receive FDA approval any malignancy. The role drugs evolving, its potential combination well means overcoming chemotherapy resistance. In this review, we discuss alterations non-Hodgkin lymphomas provide an overview current their practice, on-going trials.